Adlai Nortye Group (ANL) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed MannKind (MNKD) over the past year, gaining 796.5% versus a loss of 37.1%. MannKind is the larger company by market cap ($1.06 billion vs $1.01 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | MNKD |
|---|---|---|
| Share price | $15.62 | $3.29 |
| Market cap | $1.01B | $1.06B |
| 1-day change | +0.71% | -3.80% |
| YTD return | +992.25% | -39.68% |
| 1-year return | +796.53% | -37.13% |
| 5-year return | — | -32.81% |
| Forward P/E | — | 25.80 |
| EPS (TTM) | $-0.66 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $6.51 |
| 52-week low | $0.879 | $2.23 |
| Distance from 52-week high | -9.45% | -49.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.86% | +138.30% |
| Average volume | 187.30K | 4.50M |
| Shares outstanding | 58.73M | 321.54M |
| Employees | 109 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed MNKD by 833.7 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
ANL vs MNKD FAQ
Which is bigger, Adlai Nortye Group or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.06B compared with $1.01B for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or MNKD?
ANL returned +796.53% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and MannKind in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.